Dr. Erez Eitan to Attend the 2026 Parkinson’s Disease Therapeutics Conference

We are pleased to announce that Dr. Erez Eitan, NeuroDex’s CEO&CSO, will attend The Michael J. Fox Foundation’s 18th annual Parkinson’s Disease Therapeutics Conference (PDTC), taking place October 14–15, 2026, in New York City.

The Parkinson’s Disease Therapeutics Conference brings together leaders from academia, biotechnology, pharmaceutical companies, and the broader Parkinson’s research community to discuss advances in therapeutic development and translational research.

Advancing Blood-Based Biomarkers for Parkinson’s Disease

At NeuroDex, Dr. Eitan leads the development of technologies designed to provide a window into the brain through a standard blood sample.

NeuroDex’s ExoSORT™ platform isolates neuron-derived extracellular vesicles (NDEs) from plasma, enabling the measurement of neuronal proteins and signaling pathways that can be difficult to assess using conventional blood-based approaches.

The technology is being applied across neurodegenerative diseases, including Parkinson’s disease, to support the development of blood-based biomarkers for patient stratification, disease characterization, and assessment of biological response to therapy.

NeuroDex has also worked extensively with Parkinson’s disease samples and research programs, including studies supported by The Michael J. Fox Foundation and analyses involving samples from the Parkinson’s Progression Markers Initiative (PPMI).

Connecting at PDTC 2026

Dr. Eitan looks forward to connecting with researchers, biotechnology and pharmaceutical companies, and other organizations developing new therapies and biomarkers for Parkinson’s disease.

If you are attending PDTC and are interested in discussing neuron-derived extracellular vesicles, blood-based biomarkers, target engagement, patient stratification, or potential research collaborations, we invite you to schedule a meeting with Dr. Eitan while he is in New York.

To arrange a meeting, please contact us at info@neurodex.co.